Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Maeve Leahy"'
Autor:
Treen Carson Michael Morris, Mary B. Drake, Paul J. Kettle, Tracey McGuigan, Maeve Leahy, Michael O’Dwyer, Helen Enright, Tanya O’Shea, Rakesh Popat, Heather E. Oakervee, Kwee Yong, Jamie D. Cavenagh, David A. Cairns, Alberto Alvarez-Iglesias, Gordon Cook
Publikováno v:
Clinical Hematology International, Vol 3, Iss 1 (2021)
When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated patients was much superior to that elicited by conventional chemotherapeutic agents. We demonstrated the efficacy of PAD in re
Externí odkaz:
https://doaj.org/article/7d350a751f22432da2c884a28ef2b5bf
Autor:
David A Cairns, Alberto Alvarez-Iglesias, Helen Enright, Tracey McGuigan, M. Drake, Gordon Cook, Rakesh Popat, Heather Oakervee, Jamie Cavenagh, Tanya O’Shea, Maeve Leahy, P Kettle, Michael O'Dwyer, Treen C. M. Morris, Kwee Yong
Publikováno v:
Morris, T C M, Drake, M B, Kettle, P J, McGuigan, T, Leahy, M, O'Dwyer, M, Enright, H, O'Shea, T, Popat, R, Oakervee, H E, Yong, K, Cavenagh, J D, Cairns, D A, Alvarez-Iglesias, A & Cook, G 2021, ' How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma ', Clinical hematology international, vol. 3, no. 1, pp. 27-33 . https://doi.org/10.2991/chi.k.210201.001
Clinical Hematology International, Vol 3, Iss 1 (2021)
Clinical Hematology International
Clinical Hematology International, Vol 3, Iss 1 (2021)
Clinical Hematology International
When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated patients was much superior to that elicited by conventional chemotherapeutic agents. We demonstrated the efficacy of PAD in re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5de9777f3b787aeec01a78b049bf23
https://pure.qub.ac.uk/en/publications/f92919e9-c0f1-4ad7-83d8-287eab7c95c1
https://pure.qub.ac.uk/en/publications/f92919e9-c0f1-4ad7-83d8-287eab7c95c1
Autor:
Mary R. Cahill, Kathleen Scott, Johanna Kelly, Hilary O'Leary, Michael O'Dwyer, Fiona Quinn, Andrew Hodgson, Elisabeth Vandenberghe, Niamh Appleby, Gerard Crotty, Brian Hennessy, Liam Smyth, Helen Enright, Imelda Parker, Maeve Leahy, Amjad Hayat, David O'Brien
Publikováno v:
Leukemia & Lymphoma. 59:1338-1347
Minimal residual disease negative complete response (MRD-negative CR) provides an early marker for time to treatment failure (TTF) in CLL treated with fludarabine, cyclophosphamide, and rituximab (FCR). MRD was assessed after four FCR cycles (FCR4);
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69048f736ffe1ed698069c7686951f22
https://doi.org/10.1080/10428194.2017.1376746
https://doi.org/10.1080/10428194.2017.1376746
Autor:
Paul Browne, Brian Hennessy, M. Perera, M. Ryan, Eibhlin Conneally, D. O'Brien, Elisabeth Vandenberghe, Maeve Leahy, Gerard Crotty, J. Kelly, Catherine M. Flynn, Michael Jeffers, Patrick Hayden, Liam Smyth, F. Jackson, Fiona Quinn
Publikováno v:
Irish Journal of Medical Science (1971 -). 185:773-777
Sporadic Burkitt lymphoma (BL), characterised by translocation-associated C-MYC upregulation is a rare, aggressive lymphoma with a cure rate up to 90 % using the R-CODOX-M/R-IVAC (RCRI) protocol. RCRI is active in HIV-associated BL in combination wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa20bd3daa8149dbf7d5927a999801a3
https://doi.org/10.1007/s11845-015-1288-3
https://doi.org/10.1007/s11845-015-1288-3
Autor:
Maeve Leahy, Ryan McArthur, Tarig Mohammed Abkur, Hilary O'Leary, Denis O'Keeffe, Saad Zeinalabdin Ahmed, Mamoun Saeed
Publikováno v:
Clinical Case Reports
Key Clinical Message The decision for PJP prophylaxis depends on a physician's evaluation of multiple variables. The high rate of PJP infection described in this article combined with the known impaired T-cell function post Bendamustine treatment jus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69d8a568e74f565b903d29e2db9d5334
https://doi.org/10.1002/ccr3.195
https://doi.org/10.1002/ccr3.195
Autor:
Michael O'Dwyer, Maeve Leahy, Oonagh Gilligan, Denis O'Keeffe, Larry Bacon, Irfan Khan, Brian Hennessy, Mary Ryan, Jean Saunders, Matthew Goodyer, Mary R. Cahill, Philip Murphy, Aisling Nee, Suzanne McPherson, Su Wai Maung, Hilary O'Leary, Peter O'Gorman, Helen Enright, Fred Jackson, Johnny McHugh
Publikováno v:
British Journal of Haematology. 163:118-122
This retrospective analysis assessed the response, safety and duration of response to standard dose rituximab 375 mg/m(2) weekly for four weeks as therapy for patients with primary or secondary warm autoimmune haemolytic anaemia (WAIHA), who had fail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61729209c00edcc23bcdfbaa2d06f9a4
https://doi.org/10.1111/bjh.12486
https://doi.org/10.1111/bjh.12486
Autor:
Chul Won Choi, D. Tibullo, Han-Na Kang, Eunice Sindhuvi Edison, Philippe Schafhausen, Johanna Kelly, F. Stagno, Dan Douer, Nicolaus Kröger, Anastasia Kalpaka, Eun Hae Cho, Emmanouil Sinakos, Vasilios Perifanis, Fabienne Jouen, P. Vigneri, Wei-Hung Weng, Efthimia Vlachaki, A. Chiarenza, Jean Marc Kerleau, Judith Dierlamm, Jun Suk Kim, Young Joon Yang, Ulrike Bacher, Sunday Ocheni, Prapaporn Panichob, Karl Haslam, Ji Chan Park, Philippos Klonizakis, So Young Shin, Carsten Bokemeyer, Hongwei Wang, Gülsan Türköz Sucak, Xiling Qi, Suthat Fucharoen, Sicheng Bian, Pilar Lardelli, C. Giallongo, Münci Yağcı, Mirela Cartoafa, Torsten Haferlach, Young Yoo, A A Oyekunle, Khaldoon Alawneh, Ramachandran V. Shaji, Jung-Lim Kim, P. Spina, Aining Xu, Wasinee Kheansaard, Elif Suyanı, Sang-Guk Lee, G.A. Palumbo, Druck Reinhardt Druck Basel, Claus Meyer, P. La Cava, Alok Srivastava, Mammen Chandy, F. Di Raimondo, Dalina I. Tanyong, Zhifang Xu, Yanhong Tan, Linlin Zhang, Seung Hwan Oh, Chrisoula Pasvanti, Axel R. Zander, Elena Roy, Elisabeth Vandenberghe, Tae Sung Park, Michaël Loschi, N. Parrinello, Stephen E. Langabeer, Rolf Marschalek, Satz Mengensatzproduktion, Maeve Leahy, Fabrice Jardin, Mahmoud H. Ayesh, Hervé Tilly, Arturo Soto-Matos, A. Branca, Lee-Yung Shih, Myoung Hee Kang, Paschalis Paschos, Xiuhua Chen, Carmen Kahatt, C. Conticello, Stephen V. Liu
Publikováno v:
Acta Haematologica. 126:I-IV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3856afe1bd5b7f60fe8734ba7fed9c80
https://doi.org/10.1159/000334123
https://doi.org/10.1159/000334123
Autor:
Melanie J. Percy, Karl Haslam, Margaret Murray, Patrick Thornton, Jeremy Sargent, Brian Hennessy, Stephen E. Langabeer, Eibhlin Conneally, Amjad Hayat, Jennifer Linders, Karen Murphy, Fionnuala Ní Áinle, Maeve Leahy
Publikováno v:
Familial cancer. 13(4)
The myeloproliferative neoplasms (MPN) are clonal, hematological malignancies that include polycythemia vera, essential thrombocythemia and primary myelofibrosis. While most cases of MPN are sporadic in nature, a familial pattern of inheritance is we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ceb306475008247f266953f20fb96b2
https://pubmed.ncbi.nlm.nih.gov/25103330
https://pubmed.ncbi.nlm.nih.gov/25103330
Autor:
Gerard Crotty, Elisabeth A. Vandenberghe, David O'Brien, Kathleen Scott, Niamh Appleby, Mary R. Cahill, Johanna Kelly, Hilary O'Leary, Brian Hennessy, Michael O'Dwyer, Amjad Hayat, Smyth Liam, Helen Enright, Andrew J. Hodgson, Fiona Quinn, Imelda Parker, Maeve Leahy
Publikováno v:
Blood. 128:3237-3237
Fludarabine, cyclophosphamide and rituximab (FCR) therapy results in a complete remission (CR) rate of 72% and a median progression free survival (PFS) of 80 months in non-del (17P) CLL1. Achieving an MRD negative (MRD-ve) CR after completing therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34c5b5855852194a5495c19f5f552aa9
https://doi.org/10.1182/blood.v128.22.3237.3237
https://doi.org/10.1182/blood.v128.22.3237.3237
Autor:
Aine Burke, Denis O'Keeffe, Maeve Leahy, Gerard Crotty, Amjad Hayat, Su Wai Maung, Michael O'Dwyer, Peter O'Gorman, Patrick Thornton, Cian McEllistrim, Helen Enright, Emma M Groarke, Johnny McHugh, Margaret Murray, Ronan Desmond, Carmel Weldon, Meegahage Ratnakanthi Perera, Cathie Burke
Publikováno v:
Blood. 126:5258-5258
Introduction Myelodysplastic Syndromes are diverse group of bone marrow failure syndromes and current treatment options are guided by International Prognostic scoring systems (IPSS and IPSS-R) based on clinical phenotype and cytogenetics. Deletion of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b1835e7a6e999b8d30f4eed073100a3
https://doi.org/10.1182/blood.v126.23.5258.5258
https://doi.org/10.1182/blood.v126.23.5258.5258